BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37144811)

  • 1. Hypothyroidism in induction chemotherapy of children with acute lymphoblastic leukaemia: A single-centre study.
    Yu H; Han J; Wu X; Qiu Y; Yu H; Xu J; Hao J; Peng Y; Jin R; Zhou F
    Int J Cancer; 2023 Aug; 153(3):669-680. PubMed ID: 37144811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
    Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
    Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. THYROID DISEASE IN THE LATE OBSERVATION PERIOD UPON CHEMO AND RADIOTHERAPY IN CHILDREN/SURVIVORS OF ACUTE LYMPHOBLASTIC LEUKEMIA.
    Bebeshko VG; Bruslova KM; Lyashenko LO; Tsvіetkova NM; Galkina SG; Yaroshenko ZS; Gonchar LO; Boyarska OY; Kuzmenko VF; Trykhlib IV; Kavardakova NV
    Probl Radiac Med Radiobiol; 2021 Dec; 26():309-318. PubMed ID: 34965557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
    Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
    Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
    Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Chemotherapy Response in Childhood Acute Lymphoblastic Leukaemia and its Correlation with Cytogenetic and Molecular Features.
    Rana NA; Mahmood A; Robert HM; Zahir S; Ali I; Riaz S
    J Coll Physicians Surg Pak; 2022 Nov; 32(11):1430-1434. PubMed ID: 36377010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
    Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
    Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
    Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL].
    Li J; Zhang ZB; Liu ZR; Yang M; Nie YX; Wu MM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1011-1015. PubMed ID: 30111399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.
    Gao R; Liang JH; Wang L; Zhu HY; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Yang T; Li JY; Xu W
    Br J Haematol; 2017 Apr; 177(1):95-105. PubMed ID: 28146267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
    Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
    Balduzzi A; Valsecchi MG; Uderzo C; De Lorenzo P; Klingebiel T; Peters C; Stary J; Felice MS; Magyarosy E; Conter V; Reiter A; Messina C; Gadner H; Schrappe M
    Lancet; 2005 Aug 20-26; 366(9486):635-42. PubMed ID: 16112299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.